Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and Nuvation Bio (NYSE:NUVB – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares Voyager Therapeutics and Nuvation Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $34.46 million | 3.67 | -$119.72 million | ($1.80) | -1.14 |
| Nuvation Bio | $169.90 million | 10.03 | -$204.63 million | ($0.44) | -11.03 |
Voyager Therapeutics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Voyager Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Profitability
This table compares Voyager Therapeutics and Nuvation Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -312.63% | -57.92% | -45.00% |
| Nuvation Bio | -88.18% | -46.59% | -22.01% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Voyager Therapeutics and Nuvation Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
| Nuvation Bio | 1 | 2 | 9 | 0 | 2.67 |
Voyager Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 704.49%. Nuvation Bio has a consensus target price of $13.22, indicating a potential upside of 172.34%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Nuvation Bio.
Summary
Nuvation Bio beats Voyager Therapeutics on 10 of the 15 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
